<DOC>
	<DOCNO>NCT02219490</DOCNO>
	<brief_summary>The purpose study evaluate Long-term outcome follow treatment ABT-450/r/ABT-267 ABT-333 without RBV adult genotype 1 Chronic Hepatitis C Virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 ( ABT-450/r/ABT-267 ) ABT-333 With Without Ribavirin ( RBV ) Adults With Genotype 1 Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>1 . Males female least 18 year old screen 2 . Females must postmenopausal 2 year surgically sterile practice acceptable form birth control 3 . Chronic hepatitis C , genotype 1 infection 4 . Males must surgically sterile agree practice acceptable form birth control 5 . Screening laboratory result indicate HCV genotype 1 infection 1 . Use contraindicate medication within 2 week dose 2 . Abnormal laboratory test 3 . Current past clinical evidence ChildPugh B C classification history liver decompensation 4 . Confirmed presence hepatocellular carcinoma 5 . History solid organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non responder</keyword>
	<keyword>Null responder</keyword>
	<keyword>Treatment-Experienced</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Relapser</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Naive</keyword>
</DOC>